期刊
CANCER DISCOVERY
卷 8, 期 3, 页码 269-271出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-18-0075
关键词
-
类别
资金
- CANCER-ID - Innovative Medicines Joint Undertaking (IMIJU)
- Servier
- Austrian National Bank (ONB) [16917]
- Austrian Science Fund (FWF) [P28949-B28]
- Bio-TechMed-Graz flagship project EPIAge
- Christian Doppler Research Fund for Liquid Biopsies for Early Detection of Cancer
- Austrian Science Fund (FWF) [P28949] Funding Source: Austrian Science Fund (FWF)
In this issue of Cancer Discovery, Miyamoto and colleagues adapted their microfluidic CTC-iChip isolation platform with a digital RNA-PCR readout for eight prostate-specific transcripts and two assays for the androgen receptor mRNA splice variant ARV7 and the TMPRSS2-ERG translocation transcript. In patients with metastatic castrate-resistant prostate cancer at initiating abiraterone therapy in a first-line setting, the resulting RNA-based digital circulating tumor cell signatures identified patients with a shorter overall survival, and in patients with clinically localized disease, the signatures identified those with seminal vesicle invasion and pelvic lymph node involvement. (c) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据